<DOC>
	<DOCNO>NCT02770170</DOCNO>
	<brief_summary>The overall purpose study ass efficacy three different dos BI 655064 placebo add-on therapy standard care ( SOC ) treatment active lupus nephritis order characterize dose-response relationship within therapeutic range , select target dose phase III development .</brief_summary>
	<brief_title>Dose Finding , Efficacy Safety BI 655064 Patients With Active Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<criteria>Inclusion criterion : Males females 1870 year . Women childbearing potential must ready able use highly effective method birth control per international Conference Harmonisation M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . Diagnosis systemic lupus erythematosus ( SLE ) American College Rheumatology criterion 1997 , least 4 criterion must document , one must positive antidsDNA antibody Lupus Nephritis Class III IV ( International Society Nephrology ( ISN ) /Renal Pathology Society ( RPS ) 2003 classification ) either active active/chronic disease , coexist class V permit , proven renal biopsy within 3 month prior screen screen induction therapy yet start Active renal disease evidence proteinuria &gt; = 1.0 g/day ( Uprot/Ucrea &gt; = 100 mg/mmol ) Signed date write informed consent Exclusion criterion : Clinically significant current renal disease Glomerular Filtration Rate &lt; 30ml/min/1.73mÂ² Acute presence Oliguria ( &lt; 500 mL/day ) Dialysis within 12m screen Antiphospholipid syndrome Diabetes mellitus poorly control know diabetic retinopathy nephropathy Evidence current previous clinically significant disease , medical condition find medical examination investigator 's opinion would compromise safety patient quality data Any induction therapy Lupus Nephritis within last 6 month prior randomisation except induction Mycophenolate Mofetil high dose steroid start within 4 week prior randomisation Treatment biologic Bcell deplete therapy ( e.g . antiCD20 , antiCD22 , antiBLyS ) within 12 month prior randomisation Treatment abatacept within 12 month prior randomisation Treatment tacrolimus cyclosporin within 4 week prior randomisation Treatment cyclophosphamid within 6 month prior randomisation Treatment investigational drug within 6 month 5 halflives , whichever great randomisation Contraindication MMF corticosteroid Chronic relevant acute infection , include limited HIV , Hepatitis B C tuberculosis ( include history clinical tuberculosis ( TB ) and/or positive QuantiFERON TBGold test Any active suspected malignancy history document malignancy within last 5 year screen , except appropriately treat carcinoma situ treat basal cell carcinoma . Live vaccination within 6 week randomisation Patients unable comply protocol investigator 's opinion . Alcohol abuse opinion investigator active drug abuse . Women pregnant , nursing , plan become pregnant trial Impaired hepatic function , define serum Aspartate Transferase/Alanine Transferase , bilirubin alkaline phosphatase level &gt; 2 x Upper Limit Normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>